Showing 4961-4970 of 7518 results for "".
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest
- Medical Entrepreneur Symposium: Registration Open, Sponsors Invitedhttps://practicaldermatology.com/news/20130226-medical_entrepreneur_symposium_registration_open_sponsors_invited/2459606/The 2nd Annual The Medical Entrepreneur Symposium for physicians, office managers and physician entrepreneurs, to be held in Delray Beach, FL April 19-21, is expected to attract over 150 healthcare (and healthcare related) professionals an
- New Survey: Rosacea Inflicts Physical Discomforthttps://practicaldermatology.com/news/20120925-new_survey_rosacea_inflicts_physical_discomfort/2459731/A recent survey conducted by the National Rosacea Society (NRS) shows that significant physical discomfort often accompanies the visible signs of rosacea. In the survey of 1,709 patients with rosacea, nearly 93 percent said they had experienced physical discomfort as a result of the disorder. A burn
- Humira Talking Pen Launched to Educate on Self-injectionhttps://practicaldermatology.com/news/20120917-humira_talking_pen_launched_to_educate_on_self-injection/2459737/Abbott Laboratories, makers of Humira, released the Humira Talking Training Pen, available at no cost as part of the myHUMIRA patient support program (humira.com/m
- Interactive Education Resource for Residents Now Availablehttps://practicaldermatology.com/news/20120716-interactive_education_resource_for_residents_now_available/2459772/
- New School Initiative for Skin Cancer Preventionhttps://practicaldermatology.com/news/20120515-new_school_initiative_for_skin_cancer_prevention/2459798/La Roche-Posay recently collaborated with the Women's Dermatologic Society to launch “Time Out, Protect Your Skin” (TOPS) in schools to educate children and families about skin cancer prevention. New York City's Grace Church School was the first s
- New Technology Helps Identify Two Rare Skin Cell Subtypeshttps://practicaldermatology.com/news/20120515-new_technology_helps_identify_two_rare_skin_cell_subtypes/2459799/
- From EADV: Rezpegaldesleukin Effective Through 24 Weeks in REZOLVE-AD Trialhttps://practicaldermatology.com/news/from-eadv-rezpegaldesleukin-effective-through-24-weeks-in-rezolve-ad-trial/2483465/New data from the REZOLVE-AD presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress demonstrated that investigational IL-2 pathway agonist rezpegaldesleukin sustained effect beyond the 16-week induction period in patients with moderat
- From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Programhttps://practicaldermatology.com/news/from-eadv-povorcitinib-maintains-efficacy-through-24-weeks-in-hs-phase-3-data/2483429/New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025
- FDA Approves Topical Ruxolitinib for AD in Children Aged 2 and Uphttps://practicaldermatology.com/news/fda-approves-topical-ruxolitinib-for-ad-in-children-aged-2-and-up/2483445/The US Food and Drug Administration (FDA) has approved ruxolitinib cream 1.5% (Opzelura) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in non-immunocompromised children ages 2 and older whose disease is inadequate